NO321275B1 - Forbedret kjemisk fremgangsmate for fremstilling av tungt opploselige alkaliske salter av substituerte heterocykliske sulfinylforbindelser med farmasoytisk doseringsform og fremgangsmate for fremstilling derav. - Google Patents
Forbedret kjemisk fremgangsmate for fremstilling av tungt opploselige alkaliske salter av substituerte heterocykliske sulfinylforbindelser med farmasoytisk doseringsform og fremgangsmate for fremstilling derav. Download PDFInfo
- Publication number
- NO321275B1 NO321275B1 NO20012427A NO20012427A NO321275B1 NO 321275 B1 NO321275 B1 NO 321275B1 NO 20012427 A NO20012427 A NO 20012427A NO 20012427 A NO20012427 A NO 20012427A NO 321275 B1 NO321275 B1 NO 321275B1
- Authority
- NO
- Norway
- Prior art keywords
- omeprazole
- magnesium
- suspension
- compound
- active substance
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 36
- 239000002552 dosage form Substances 0.000 title claims description 26
- 159000000011 group IA salts Chemical class 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims description 11
- 230000008569 process Effects 0.000 title claims description 5
- 238000001311 chemical methods and process Methods 0.000 title 1
- MQEUGMWHWPYFDD-UHFFFAOYSA-N magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Mg].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-UHFFFAOYSA-N 0.000 claims description 40
- 229960003117 omeprazole magnesium Drugs 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- 239000000725 suspension Substances 0.000 claims description 25
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 21
- 229960000381 omeprazole Drugs 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000013543 active substance Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 159000000003 magnesium salts Chemical class 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- -1 piperidino, morpholino Chemical group 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000007900 aqueous suspension Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 239000003125 aqueous solvent Substances 0.000 claims description 7
- 244000052616 bacterial pathogen Species 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- 229960004770 esomeprazole Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 229940088679 drug related substance Drugs 0.000 claims description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000010410 layer Substances 0.000 description 19
- 239000008188 pellet Substances 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 229940126409 proton pump inhibitor Drugs 0.000 description 8
- 239000000612 proton pump inhibitor Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000012512 bulk drug substance Substances 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 6
- 238000009505 enteric coating Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001556 benzimidazoles Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011162 core material Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940126600 bulk drug product Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229950007395 leminoprazole Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9803953A SE9803953D0 (sv) | 1998-11-18 | 1998-11-18 | Improved chemical process |
| SE9803952A SE9803952D0 (sv) | 1998-11-18 | 1998-11-18 | Pharmaceutical formulation |
| PCT/SE1999/002093 WO2000028975A2 (en) | 1998-11-18 | 1999-11-15 | Improved chemical process and pharmaceutical formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012427D0 NO20012427D0 (no) | 2001-05-16 |
| NO20012427L NO20012427L (no) | 2001-07-09 |
| NO321275B1 true NO321275B1 (no) | 2006-04-10 |
Family
ID=26663439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012427A NO321275B1 (no) | 1998-11-18 | 2001-05-16 | Forbedret kjemisk fremgangsmate for fremstilling av tungt opploselige alkaliske salter av substituerte heterocykliske sulfinylforbindelser med farmasoytisk doseringsform og fremgangsmate for fremstilling derav. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6403616B1 (de) |
| EP (1) | EP1131316B1 (de) |
| JP (1) | JP4610086B2 (de) |
| KR (1) | KR100619200B1 (de) |
| CN (1) | CN100503598C (de) |
| AT (1) | ATE271556T1 (de) |
| AU (1) | AU770633B2 (de) |
| BR (1) | BR9915421A (de) |
| CA (1) | CA2347981C (de) |
| DE (1) | DE69918854T2 (de) |
| DK (1) | DK1131316T3 (de) |
| ES (1) | ES2222754T3 (de) |
| HK (1) | HK1038920B (de) |
| IL (2) | IL142629A0 (de) |
| NO (1) | NO321275B1 (de) |
| NZ (1) | NZ511169A (de) |
| PT (1) | PT1131316E (de) |
| WO (1) | WO2000028975A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US7799937B2 (en) | 2004-10-25 | 2010-09-21 | Synthonics, Inc. | Metal coordinated compositions |
| US8779175B2 (en) | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
| US20060141054A1 (en) * | 2004-10-25 | 2006-06-29 | Thomas Piccariello | Metal coordinated compositions |
| US20100297226A1 (en) * | 2006-06-01 | 2010-11-25 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
| ES2674348T3 (es) | 2011-11-10 | 2018-06-29 | Rotam Agrochem International Co., Ltd | Composición herbicida y método para usar la misma |
| EP3288556A4 (de) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Oral zerfallende zusammensetzungen |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| ATE156707T1 (de) | 1991-06-21 | 1997-08-15 | Ilsan Ilac Ve Hammaddeleri San | Neues galenisches verfahren für omeprazol enthaltende pellets |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| SE9302395D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| TNSN95062A1 (fr) | 1994-05-27 | 1996-02-06 | Astra Ab | Nouveaux derives dialkoxy-pyridinyle-benzimidazole |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| AUPN846496A0 (en) * | 1996-03-05 | 1996-03-28 | Research Laboratories Of Australia Pty Ltd | Electronic printing for display technology |
| SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
| CN1134667C (zh) * | 1996-05-17 | 2004-01-14 | 福姆法克特公司 | 微电子弹性接触元件 |
| CN1128997C (zh) * | 2001-01-04 | 2003-11-26 | 中国科学院南京土壤研究所 | 一种吸力平板的制作方法 |
-
1999
- 1999-11-15 ES ES99962610T patent/ES2222754T3/es not_active Expired - Lifetime
- 1999-11-15 JP JP2000582023A patent/JP4610086B2/ja not_active Expired - Fee Related
- 1999-11-15 DK DK99962610T patent/DK1131316T3/da active
- 1999-11-15 NZ NZ511169A patent/NZ511169A/xx not_active IP Right Cessation
- 1999-11-15 BR BR9915421-8A patent/BR9915421A/pt active Search and Examination
- 1999-11-15 PT PT99962610T patent/PT1131316E/pt unknown
- 1999-11-15 WO PCT/SE1999/002093 patent/WO2000028975A2/en active IP Right Grant
- 1999-11-15 CA CA2347981A patent/CA2347981C/en not_active Expired - Fee Related
- 1999-11-15 AU AU19017/00A patent/AU770633B2/en not_active Ceased
- 1999-11-15 AT AT99962610T patent/ATE271556T1/de active
- 1999-11-15 CN CNB998133280A patent/CN100503598C/zh not_active Expired - Fee Related
- 1999-11-15 DE DE69918854T patent/DE69918854T2/de not_active Expired - Lifetime
- 1999-11-15 IL IL14262999A patent/IL142629A0/xx active IP Right Grant
- 1999-11-15 US US09/485,897 patent/US6403616B1/en not_active Expired - Lifetime
- 1999-11-15 EP EP99962610A patent/EP1131316B1/de not_active Expired - Lifetime
- 1999-11-15 KR KR1020017006233A patent/KR100619200B1/ko not_active IP Right Cessation
-
2001
- 2001-04-16 IL IL142629A patent/IL142629A/en not_active IP Right Cessation
- 2001-05-16 NO NO20012427A patent/NO321275B1/no not_active IP Right Cessation
-
2002
- 2002-01-21 HK HK02100464.5A patent/HK1038920B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1038920A1 (en) | 2002-04-04 |
| AU1901700A (en) | 2000-06-05 |
| US6403616B1 (en) | 2002-06-11 |
| IL142629A (en) | 2007-12-03 |
| EP1131316B1 (de) | 2004-07-21 |
| AU770633B2 (en) | 2004-02-26 |
| JP2002529497A (ja) | 2002-09-10 |
| JP4610086B2 (ja) | 2011-01-12 |
| CA2347981C (en) | 2010-05-04 |
| BR9915421A (pt) | 2001-08-07 |
| PT1131316E (pt) | 2004-10-29 |
| ATE271556T1 (de) | 2004-08-15 |
| NZ511169A (en) | 2003-06-30 |
| IL142629A0 (en) | 2002-03-10 |
| HK1038920B (zh) | 2005-03-11 |
| CN1326455A (zh) | 2001-12-12 |
| DK1131316T3 (da) | 2004-09-27 |
| NO20012427D0 (no) | 2001-05-16 |
| KR100619200B1 (ko) | 2006-09-05 |
| CA2347981A1 (en) | 2000-05-25 |
| WO2000028975A3 (en) | 2000-08-10 |
| WO2000028975A2 (en) | 2000-05-25 |
| EP1131316A2 (de) | 2001-09-12 |
| DE69918854D1 (de) | 2004-08-26 |
| KR20010089474A (ko) | 2001-10-06 |
| DE69918854T2 (de) | 2005-07-21 |
| CN100503598C (zh) | 2009-06-24 |
| NO20012427L (no) | 2001-07-09 |
| ES2222754T3 (es) | 2005-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2166935C2 (ru) | Таблетированная многоединичная лекарственная форма, способ ее получения, способ ингибирования секреции желудочной кислоты или лечения желудочно-кишечных заболеваний у млекопитающих и человека | |
| US7276253B2 (en) | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof | |
| CA2376226C (en) | New formulation | |
| NO328100B1 (no) | Farmasoytisk formulering av omeprazol | |
| NO319999B1 (no) | Tabletterte, brusende multippelenhet-doseringsformer omfattende en protonpumpeinhibitor, fremgangsmate for fremstilling av slike doseringsformer, og anvendelse derav. | |
| CZ20002314A3 (cs) | Orální farmaceutická dávková forma s prodlouženým uvolňováním | |
| IL229510A (en) | Solid form of tablet or tablet form for gastric juices and oral administration of pantoprazole magnesium dihydrate as active substance | |
| NO321275B1 (no) | Forbedret kjemisk fremgangsmate for fremstilling av tungt opploselige alkaliske salter av substituerte heterocykliske sulfinylforbindelser med farmasoytisk doseringsform og fremgangsmate for fremstilling derav. | |
| CA2648538C (en) | Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles | |
| ZA200103340B (en) | Improved chemical process and pharmaceutical formulation. | |
| RU2414889C2 (ru) | Фармацевтическая композиция для лечения язвы желудка и двенадцатиперстной кишки в форме твердых желатиновых капсул, содержащая рабепразол или его производные, и способ ее получения | |
| JP2005522462A (ja) | 気道疾患の治療のためのプロトンポンプ阻害剤の使用 | |
| MXPA00005896A (en) | Oral pharmaceutical extended release dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |